scholarly journals The Media's influence on the validity of medical information regarding Alzheimer's Disease

2021 ◽  
Vol 10 (2) ◽  
Author(s):  
Samhita Korukonda ◽  
Hiranmayi Pantula
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Medical Information ◽  
The Internet ◽  
Common Source ◽  
Web Browsers ◽  
Patient Awareness ◽  
The Us ◽  
The Usa ◽  
The Media

This article aims to statistically analyze misinformation regarding dementia and Alzheimer’s disease (AD) on the internet and discuss common trends amongst falsities. The internet is the most common source of medical information and is largely used by the general public to seek information about a condition/treatment. Dementia is one of the most searched conditions across online platforms. AD is the most common cause of dementia in the US and accounts for 75% of dementia cases. As the prevalence of AD increases, more patients turn to the media to seek information about its implications and treatments. With the increasingly important role that media plays in the field of medicine, families need to be aware of potential sources of misinformation. This paper analyzes one hundred total sources, then categorizes each source into one of three groups (with varying degrees of falsities): misleading, partially misleading, and reliable. The sources were collected using the keywords “Alzheimer’s disease” and included 50 videos from YouTube and 25 recommended sources from Google and Firefox respectively (Google and Firefox are some of the most used web browsers in the USA). Subsequently, a misinformed source was thematically classified based on the type of misinformation found. To verify results, all sources were reviewed by a senior geropsychiatric consultant from London, who specializes in dementia care/treatment. [Further elaborated in ‘methods’ section]   The results indicate that there is systematic misinformation on the internet. It highlights the importance of patient awareness towards this issue. On this basis, it should be recommended that provider’s offices alert their patients of this problem.

The cost-utility of the rivastigmine transdermal patch in the management of patients with moderate Alzheimer's disease in the US

2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
A Brennan ◽  
B Nagy ◽  
A Brandtmüller ◽  
SK Thomas ◽  
M Gallagher ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Utility ◽  
Transdermal Patch ◽  
The Us ◽  
The Cost

scholarly journals Cross-cultural adaptation of the German version of the Quality of Life in Alzheimer's Disease scale - Nursing Home version (QoL-AD NH)

2016 ◽  
Vol 28 (8) ◽  
pp. 1399-1400 ◽  
Author(s):  
Martin Nikolaus Dichter ◽  
Eva-Maria Wolschon ◽  
Gabriele Meyer ◽  
Sascha Köpke
Keyword(s):  
Quality Of Life ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Community Dwelling ◽  
Positive Effects ◽  
People With Dementia ◽  
The Us ◽  
Dementia Research ◽  
Almost All

Dementia is a chronic and currently incurable syndrome. Therefore, quality of life (QoL) is a major goal when caring for people with dementia (Gibson et al., 2010) and a major outcome in dementia research (Moniz-Cook et al., 2008). The measurement of QoL, especially proxy-rating, is challenging because of the proxy-perspective (Pickard and Knight, 2005), reliability (Dichter et al., 2016), validity (O'Rourke et al., 2015), and responsiveness (Perales et al., 2013). Probably due to these challenges, it has not been possible to show positive effects for QoL in almost all non-pharmacological interventions for people with dementia (Cooper et al., 2012). One recommended (Moniz-Cook et al., 2008) and frequently used instrument is the Quality of Life in Alzheimer's Disease scale (QoL-AD), which was originally developed in the US for community-dwelling people with dementia. The QoL-AD consists of 13 items based on a 4-point Likert scale ranging from “1”=poor to “4”=excellent (Logsdon et al., 1999). The original instrument has been adapted for people living in nursing homes (NH) by Edelmann et al. (2005).

scholarly journals Economic problems and the threat of the Old World: the USA media assessment

2019 ◽  
Vol 8 (4) ◽  
pp. 214-217
Author(s):  
Sergey Olegovich Buranok ◽  
Katerina Vyacheslavovna Belyaeva ◽  
Margarita Igorevna Tulusakova
Keyword(s):  
Mass Media ◽  
Formation Process ◽  
Crucial Role ◽  
Red Scare ◽  
Economic Problems ◽  
Soviet People ◽  
The Us ◽  
The Usa ◽  
The Media ◽  
Soviet Russia

The paper is dedicated to the evolutionary formation process of the American mass media perception towards the Soviet Russia during the severe Russian famine of 1921-1922, also known as the Povolzhye famine. The research novelty lies in the deep analysis of the US press assessments concerning the famine. The authors provide the results of their American newspapers examination regarding the image formation of the Soviet authorities, the Soviet people and the so-called Red Scare. The authors research included a review of the main anti-Soviet arguments made by the media; the review revealed that the Povolzhye famine image had a crucial role in the labeling Russia as a retrogressive country. Studying this informational phenomenon allows researchers to understand what impact it had on Soviet-American relations, since it directly affected the perception of Russia and the Russian/Soviet people through the media. This, in turn, might help with comprehension of some stereotypes about Russia that can still be encountered in the American public opinion to date.

scholarly journals RECRUITMENT INTO THE ALZHEIMER PREVENTION TRIALS (APT) WEBSTUDY FOR A TRIAL-READY COHORT FOR PRECLINICAL AND PRODROMAL ALZHEIMER’S DISEASE (TRCPAD)

2020 ◽  
pp. 1-7
Author(s):  
S. Walter ◽  
T.B. Clanton ◽  
O.G. Langford ◽  
M.S. Rafii ◽  
E.J. Shaffer ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Effective Means ◽  
Web Based ◽  
The Us ◽  
Study Team ◽  
Prodromal Alzheimer’S Disease ◽  
Prevention Trials ◽  
Study Participants ◽  
The Impact

BACKGROUND: The Alzheimer Prevention Trials (APT) Webstudy is the first stage in establishing a Trial-ready Cohort for Preclinical and Prodromal Alzheimer’s disease (TRC-PAD). This paper describes recruitment approaches for the APT Webstudy. Objectives: To remotely enroll a cohort of individuals into a web-based longitudinal observational study. Participants are followed quarterly with brief cognitive and functional assessments, and referred to Sites for in-clinic testing and biomarker confirmation prior to enrolling in the Trial-ready Cohort (TRC). Design: Participants are referred to the APT Webstudy from existing registries of individuals interested in brain health and Alzheimer’s disease research, as well as through central and site recruitment efforts. The study team utilizes Urchin Tracking Modules (UTM) codes to better understand the impact of electronic recruitment methods. Setting: A remotely enrolled online study. Participants: Volunteers who are at least 50 years old and interested in Alzheimer’s research. Measurements: Demographics and recruitment source of participant where measured by UTM. Results: 30,650 participants consented to the APT Webstudy as of April 2020, with 69.7% resulting from referrals from online registries. Emails sent by the registry to participants were the most effective means of recruitment. Participants are distributed across the US, and the demographics of the APT Webstudy reflect the referral registries, with 73.1% female, 85.0% highly educated, and 92.5% Caucasian. Conclusions: We have demonstrated the feasibility of enrolling a remote web-based study utilizing existing registries as a primary referral source. The next priority of the study team is to engage in recruitment initiatives that will improve the diversity of the cohort, towards the goal of clinical trials that better represent the US population.

scholarly journals Analyses of Diagnostic Patterns at 30 Alzheimer’s Disease Centers in the US

2010 ◽  
Vol 35 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Kyle Steenland ◽  
Jessica Macneil ◽  
Scott Bartell ◽  
James Lah
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
The Us

[P2-212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY

2017 ◽  
Vol 13 (7S_Part_14) ◽  
pp. P691-P692 ◽  
Author(s):  
Isabelle Bos ◽  
Stephanie J.B. Vos ◽  
Rik Vandenberghe ◽  
Philip Scheltens ◽  
Sebastiaan Engelborghs ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Medical Information ◽  
Biomarker Discovery ◽  
Information Framework

INSIDE INDUSTRY

2015 ◽  
Vol 19 (04n05) ◽  
pp. 59-64
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Decline ◽  
Human Disease ◽  
Amyloid Plaque ◽  
License Agreement ◽  
Disease Therapy ◽  
The Us

Biogen Idec's Aducanumab (BIIB037) shown to reduce brain amyloid plaque levels slow cognitive decline in patients with prodromal or mild Alzheimer's disease. Johnson Matthey recognized in 2015 CMO Leaderships Awards. Heraeus enters agreement to acquire NeoMetrics. AstraZeneca and Daiichi Sankyo to jointly commercialize MOVANTIK in the US. AbbVie and C2N enter worldwide license agreement for Alzheimer's disease therapy. Menara Landmark Medical Suites expands healthcare and medical offerings in Johor Bahru. Sigma-Aldrich® expands customer-centric model with investments in Singapore. NTU setting up a new $30 million institute to boost Singapore's efforts in tackling human disease.

Sign in / Sign up

Export Citation Format

Share Document